Berlin / Boston, June 29, 2022 – Bayer AG announced nowadays the opening of its new Exploration and Innovation Heart at Kendall Square in Boston-Cambridge, Massachusetts (U.S.A.), growing further more the company’s footprint into 1 of the world’s most modern pharmaceutical exploration and growth places. Symbolizing a total $140M USD investment decision into the area, Bayer’s 62,100-square-foot creating homes a new middle of precision molecular oncology study geared up with condition-of-the-artwork laboratories and places of work for the growth of novel targeted cancer therapies for individuals. In addition, the heart comprises a recently set up research staff centered on leveraging chemical biology strategies to even more propel the company’s oncology drug advancement system.
“Our new Bayer research and innovation center at Kendall Square is portion of our tactic to be at the forefront of scientific discovery and breakthrough innovation for superior patient health care,” claimed Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer’s Prescribed drugs Division. “Currently being aspect of this exclusive innovation ecosystem will assist our teams in making breakthrough innovations for individuals alongside one another with the gurus in this article.”
“Bayer has a increasing group of world-course innovators – from our inside authorities and associates these types of as Vividion, to our world network of educational and market companions, many of which are found right below in the Boston region,” mentioned Christian Rommel, Member of the Govt Committee of Bayer AG’s Pharmaceutical Division and Head of Investigate and Advancement at Bayer. “Our new study and innovation center in Kendall Square provides us closer to these companions, to fellow scientists and institutions that sign up for us in our mission to continue to keep pushing the boundaries of health-related innovation with the intent of bringing impactful health and fitness methods to patients.”
“We have introduced a quantity of unique oncology treatment plans to individuals more than the earlier decades,” reported Christine Roth, Member of the Govt Committee of Bayer’s Pharmaceutical Division and Head of the Oncology SBU at Bayer. “Our ambition is to perform a significant role in the following wave of breakthrough improvements in oncology. The opening of our new research centre at Kendall Sq. with its focused study team of precision oncology gurus demonstrates our dedication to investing in the future wave of innovation that has the likely to effects the way most cancers is dealt with.”
“At Kendall Sq., we uncover the innovation-driven firms, entrepreneurship, globe-class academics, slicing-edge analysis, breakthrough systems, infrastructure, and culture to help our strategic objectives,” stated Marianne De Backer, MBA, Ph.D., Member of the Government Committee of the Prescription drugs Division and Head of Approach, Small business Enhancement & Licensing and Open up Innovation at Bayer. “It assists us to more solidify our existence and commitment in this lively and developing ecosystem that offers us an option to link with existing and long run pioneers in the pharmaceutical sector. We are right here to establish extensive-lasting interactions that will speed up our quest for novel remedies and technologies. Together, we will leverage our cumulative abilities and assets, and certainly remodel affected person lives.”
Spanning across two floors, the new heart now offers house for one hundred personnel, when the enterprise is geared up to fill an extra fifty roles in the coming months. It is developed to increase the collaboration among Bayer exploration and progress, its inner companions these types of as BlueRock Therapeutics, Asklepios BioPharmaceutical (AskBio) and Vividion Therapeutics, as nicely as exterior companions to speed up the progress of transformative therapies for people. In addition to the new middle at Kendall Sq. in Cambridge, Bayer has also recognized strategic research collaborations with leading scientific companions in Boston, together with joint laboratories in the locations of lung sickness with Brigham and Women’s Medical center and Massachusetts General Hospital and precision cardiology with the Broad Institute of MIT and Harvard.
The Investigation and Innovation Centre also marks a strategic expense into Bayer’s oncology innovation to completely transform health care for people dwelling with most cancers around the globe, and at the exact time to make sure sustainable extensive-time period progress for the firm. Striving to develop into a top rated ten oncology organization by 2030, Bayer is investing a considerable part of its international R&D price range towards oncology. The new precision molecular oncology research middle will generate the improvement of targeted following-era most cancers therapies, such as attempts to support persons dwelling with cancer benefit from molecular checks and specific therapies via biomarker testing.
Bayer has a one hundred sixty-year track record of offering scientific innovation for patients in spots of superior medical want and has prolonged embraced external innovation and partnering. Considering the fact that 2020, Bayer has secured extra than forty transactions in enterprise improvement and licensing and invested $one.5B USD in partnerships by its Leaps by Bayer effect investments, and the new middle is expected to enjoy a part for upcoming partnering investments and collaborations.
With this new middle, Bayer is growing its functions in the leading everyday living sciences cluster throughout the world. Boston-Cambridge is house to around 1,000 biotechnology providers, with Kendall Sq. becoming the center of pharmaceutical innovation on the East Coastline of the United states of america. The company is now present in 4 of the premier biotechnology hubs in the United States – Boston, San Francisco, San Diego and Research Triangle Park, NC.
Bayer is a worldwide enterprise with core competencies in the daily life science fields of well being care and nourishment. Its products and expert services are made to assistance folks and the world prosper by supporting efforts to learn the big challenges presented by a rising and growing older international population. Bayer is fully commited to driving sustainable development and making a positive effects with its firms. At the identical time, the Group aims to enhance its earning electric power and develop benefit through innovation and growth. The Bayer brand name stands for have confidence in, dependability and quality in the course of the earth. In fiscal 2021, the Group used all over 100,000 folks and experienced profits of 44.1 billion euros. R&D costs before specific things amounted to 5.three billion euros. For far more data, go to www.bayer.com.
This launch may perhaps consist of forward-hunting statements based mostly on present-day assumptions and forecasts built by Bayer management. Several identified and mysterious challenges, uncertainties and other elements could guide to substance differences involving the precise future final results, economic predicament, advancement or performance of the firm and the estimates provided listed here. These variables incorporate those talked over in Bayer’s general public reports which are available on the Bayer web page at www.bayer.com. The firm assumes no legal responsibility by any means to update these forward-wanting statements or to conform them to potential situations or developments.